Tofanib 5 mg tablet contains tofacitinib, an immunosuppressant that reduces inflammation by blocking certain immune signals. It is used in adults with rheumatoid arthritis and other immune-related conditions when other treatments have not worked well enough.
There are 13 brands of Tofacitinib listed in Bangladesh. 1 of them has a lower unit price than Tofanib. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.
What is Tofanib 5 mg Tablet?
Tofanib 5 mg tablet is a medicine that acts on the immune system to help control inflammation in conditions such as rheumatoid arthritis. It belongs to a group called immunosuppressants and works by blocking specific signals inside immune cells, which can reduce joint pain and swelling. Doctors prescribe it for adults whose condition has not responded well to other treatments. Because it affects the immune system, it requires careful medical supervision. The dose and course are decided by your doctor, and regular monitoring may be needed.
Uses of Tofanib
Tofanib 5 mg tablet is used to treat moderately to severely active rheumatoid arthritis in adults who have not responded well to or cannot tolerate methotrexate. It may be used alone or together with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. It is also used for other immune-related conditions as determined by a doctor. Your doctor will decide if this medicine is suitable for you.
How to use Tofanib
Tofanib 5 mg tablet is taken by mouth. The dose and how often you take it are decided by your doctor, based on your condition and other medicines you take. Swallow the tablet with water. Do not change the dose or stop taking it without talking to your doctor. If you have kidney or liver problems, your doctor may adjust the dose. Always follow your doctor's instructions.
Side effects of Tofanib
Common side effects include upper respiratory tract infections, headache, diarrhea and nasopharyngitis (inflammation of the nose and throat). Because this medicine affects the immune system, serious infections can occur. Tell your doctor if you develop fever, cough, or other signs of infection. Your doctor may monitor your blood counts and liver tests. Report any unusual symptoms or side effects to your doctor promptly.
Safety and precautions
Tofanib 5 mg tablet should not be started if you have an active serious infection. It may increase the risk of infections and gastrointestinal perforations. Live vaccines should be avoided during treatment. Your doctor will check your blood counts, liver enzymes and lipids before and during treatment. It is not recommended if your lymphocyte or neutrophil counts or hemoglobin are too low. Pregnancy category C: use during pregnancy only if the potential benefit justifies the potential risk. It is not known if it passes into breast milk; discuss breastfeeding with your doctor. Tell your doctor about all your medical conditions and medicines before starting.
Frequently asked questions
What is Tofanib 5 mg tablet used for and what kind of medicine is it?
Tofanib 5 mg tablet is an immunosuppressant containing tofacitinib. It is used to treat moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate. It may also be used for other immune-related conditions as decided by your doctor.
How should I take Tofanib 5 mg tablet?
Take Tofanib 5 mg tablet exactly as your doctor tells you. The dose and how often you take it are decided by your doctor based on your condition and other medicines. Do not change the dose or stop taking it without talking to your doctor.
What medicines can interact with Tofanib 5 mg tablet?
Tofanib 5 mg tablet can interact with medicines that affect certain liver enzymes. These include ketoconazole, fluconazole and rifampin. Your doctor may adjust your dose or avoid certain combinations. Tell your doctor about all medicines, supplements and herbal products you take before starting treatment.
Rheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic ... Read moreRheumatoid Arthritis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Pharmacology
Rheumatoid arthritis is an autoimmune disease characterized by a dysregulation of pro-inflammatory cytokines including IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines signalling results in tissue inflammation and joint damage by stimulating the recruitment and activation of immune cells via the janus kinase signalling pathway.
Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
Dosage & Administration
Rheumatoid Arthritis: Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
Interaction
Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
Side Effects
The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with Tofacitinib monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.
Pregnancy & Lactation
Pregnancy Category C. There are no adequate and well controlled studies in pregnant women. Tofacitinib should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
Precautions & Warnings
Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections.
Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
Immunizations: Live vaccines: Avoid use with Tofacitinib.
Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
Storage Conditions
Store below 30°C. Protect from light & moisture. Keep all medicines out of the reach of children.
Alternative brands of Tofacitinib
Other brands with the same generic name, cheapest first.